Overview
Traditional Chinese Medicine or Low-dose Dexamethasone in COVID-19 Pneumonia
Status:
Recruiting
Recruiting
Trial end date:
2024-12-31
2024-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The goal of this type of clinical trial is to learn about symptomatic patients with post-COVID-19 parenchymal lung abnormalities. The main questions it aims to answer are: the efficacy and safety of low-dose dexamethasone or traditional Chinese medicine in symptomatic patients with post-COVID-19 parenchymal lung abnormalities. Participants will be divided into three parallel groups:controlled group with conventional western medicine treatment including oxygen therapy, antibiotics, nebulization therapy, etc. dexamethasone group: dexamethasone 1.5mg/day for one week and 0.75mg/day for another week basing on conventional western medicine. Chinese medicine group: Strengthening spleen and tonifying lung decoction for 2 weeks basing on conventional western medicine.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
China-Japan Friendship HospitalTreatments:
Dexamethasone
Criteria
Inclusion Criteria:- Clinical diagnosis of COVID-19 pneumonia;
- 3 to 8 weeks after the onset of the first symptoms of COVID-19 infection;
- Modified Medical Research Council (mMRC) score ⩾2 or hypoxemia;
- Imaging severity assessment of pneumonia: CT severity scores (CTSS):≥5;
- Signed the informed consent.
Exclusion Criteria:
- Participants still admitted to intensive care unit at the time of enrollment;
- Known prior structural lung disease, including pulmonary fibrosis, severe COPD, severe
bronchiectasis, and lung destruction;
- Taking glucocorticoids or immunosuppressants because of other chronic diseases;
- Contraindications of glucocorticoid;
- Heart failure(NYHA III or IV);
- Participants with renal replacement therapy;
- Psychiatric disorders or cognitive impairments;
- The expected survival time is less than six months due to diseases other than COVID-19
pneumonia.